The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W. Flinn(Tennessee Oncology), Stephan Stilgenbauer(Universität Ulm), Scott D. Lunin(Florida Cancer Specialists & Research Institute), Barry Turnbull(Verastem (United States)), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Alan P Skarbnik(Novant Health), Árpád Illés(University of Debrecen), Julio Delgado(Departament de Salut), Florence Cymbalista(Hôpital Avicenne), Craig A. Portell(University of Virginia), Amanda F. Cashen(Washington University in St. Louis), Constantine S. Tam(The Alfred Hospital), Marco Montillo(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), F. Bosch(Vall d'Hebron Hospital Universitari), Matthew S. Davids(Dana-Farber Cancer Institute), Gabriel Étienne(Institut Bergonié), David T. Weaver(University of North Carolina Health Care), Paolo Ghia(Vita-Salute San Raffaele University), Zoltán Gasztonyi(Petz Aladár Megyei Oktató Kórház), Zsolt Nagy(Semmelweis University), Virginia Kelly(Verastem (United States)), Fritz Offner(Ghent University Hospital), Ulrich Jaeger(Medical University of Vienna), Bryone J. Kuss(Flinders Medical Centre)
Cited by 341
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k